Because some studies suggest that the CHEK2 1100delC variant acts as a breast cancer modifier in non-BRCA1/BRCA2 families only [5-7], we considered the subset of women known not to be BRCA1 or BRCA2 germline mutation carriers. This evidence concerns the gene BRCA2 and breast carcinoma.